LBD
EBS icon

Landsberg Bennett & Dubbaneh’s Emergent Biosolutions EBS Stock Holding History

Landsberg Bennett & Dubbaneh’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-6,931
Closed -$558K – 268
2021
Q1 		$558K Buy
6,931
+1,537
+28% +$157K 0.08% 157
2020
Q4 		$483K Buy
+5,394
New +$495K 0.07% 160

Other funds holding EBS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Landsberg Bennett & Dubbaneh's EBS Position: Q2 2021 in Review

Landsberg Bennett & Dubbaneh sold out of Emergent Biosolutions (EBS) in Q2 2021, closing a stake of 6,931 shares — an estimated $558K sold.

Landsberg Bennett & Dubbaneh first reported a position in EBS in Q4 2020 and held it in 2 quarters. The position peaked at $558K in Q1 2021. 290 funds tracked by Wall St. Rank hold EBS as of Q2 2021.

  • Landsberg Bennett & Dubbaneh reported no remaining Emergent Biosolutions position as of Q2 2021 after selling out during the quarter.
  • Landsberg Bennett & Dubbaneh sold 6,931 Emergent Biosolutions shares in Q2 2021, an estimated $558K.
  • Landsberg Bennett & Dubbaneh first reported a position in Emergent Biosolutions in Q4 2020 and held it in 2 quarters.
  • Landsberg Bennett & Dubbaneh's Emergent Biosolutions position peaked at $558K in Q1 2021.
  • 290 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2021.

Based on Landsberg Bennett & Dubbaneh's 13F filing for Q2 2021, filed 29 Jul 2021.